Scientists test Double-Punch combo to fight tough kidney cancer
NCT ID NCT03092856
Summary
This study is testing whether adding an experimental immune-boosting drug (PF-04518600) to a standard cancer drug (axitinib) works better than the standard drug alone for people with advanced kidney cancer that has spread. The goal is to see if the combination can better control the cancer's growth and keep it from getting worse for a longer time. The trial is for patients whose cancer has continued to grow despite prior immunotherapy treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
-
Los Angeles County-USC Medical Center
Los Angeles, California, 90033, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California, 92663, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22903, United States
-
Weill Cornell Medical College, New York- Presbyterian Hospital
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.